Bruker (BRKR) Expected to Announce Quarterly Earnings on Wednesday

Bruker (NASDAQ:BRKR) will likely be announcing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of $0.4188 per share and revenue of $865.16 million for the quarter. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Individuals can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11. The company had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. During the same quarter in the previous year, the firm posted $0.32 earnings per share. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, analysts expect Bruker to post $2.12 EPS for the current fiscal year and $2.40 EPS for the next fiscal year.

Bruker Trading Up 4.3%

NASDAQ:BRKR opened at $60.74 on Wednesday. The business’s fifty day moving average is $58.79 and its 200 day moving average is $50.25. Bruker has a 52-week low of $32.37 and a 52-week high of $66.98.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st were paid a $0.05 dividend. The ex-dividend date was Monday, September 21st. This represents a $0.20 annualized dividend and a yield of 0.3%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on BRKR. Leerink Partners upped their price target on Bruker from $60.00 to $80.00 and gave the company an “outperform” rating in a research report on Tuesday, September 29th. TD Cowen increased their price target on shares of Bruker from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 13th. Stifel Nicolaus set a $50.00 price objective on shares of Bruker in a research report on Wednesday, August 5th. UBS Group started coverage on shares of Bruker in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $65.00 price objective for the company. Finally, Guggenheim boosted their price objective on shares of Bruker from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $59.43.

Insider Transactions at Bruker

In other Bruker news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total value of $105,740.00. Following the transaction, the vice president directly owned 134,806 shares in the company, valued at $7,127,193.22. This represents a 1.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 27.20% of the company’s stock.

Bruker Company Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.